BackCyclo Therapeutics Overview

Cyclo Therapeutics Total Revenue

Cyclo Therapeutics's total revenue is $870K, below the Healthcare sector average of $110B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$233772.00
↓ 52.82% YoY

As of Sep 2024

Annual Revenue (TTM)

$870725.00
↓ 8.52% YoY

Trailing 12 months ending Sep 2024

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Cyclo Therapeutics (CYTH) FAQ

The latest total revenue for CYTH is $870K as of September 2024. That compares with $950K in the prior-year period — down 8.5% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Cyclo Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CYTH's total revenue moved from $950K to $870K — a 8.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cyclo Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, CYTH currently prints $870K for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Cyclo Therapeutics's growth, margins, and balance sheet.

A total revenue figure of $870K for CYTH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting CYTH's total revenue ($870K), review year-over-year change from $950K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.